Atypical Presentation of Triple-Negative Breast Cancer
Ramon Eduardo Garcia-Cahuich, Felipe Rodríguez-Solis, Nancy E. García-Carrillo, Alondra Yereldi Naranjo-Cruz, Lorena Berenice Hernández-Hoil and María Valeria Jiménez-Báez
Article Type: Case Report and Systematic Review | First Published: August 30, 2021
Triple-Negative Breast Cancer (BCTN) has been defined as the absence of Estrogenic Receptors (ER), Progesterone Receptors (EP), Epidermal growth factor receptor 2 (HER2), and it conforms 10 to 20% of all cases of breast cancer. A 42-years-old female, debuting with abdominal pain, a 44 pounds of weight loss on the last 2 months and abdominal mass presence. A single complex looking nodule found in the left breast, which underwent a biopsy with results of triple negative breast adenocarcinoma, she ...
Proposed Biology of the Spontaneous Remission of Hepatocellular Carcinoma
Article Type: Clinical Case | First Published: August 30, 2021
Case Reports of the Spontaneous regression or remission of hepatocellular carcinoma was studied. Two common factors were noted among the prolonged spontaneous remission or regression of hepatocellular carcinoma. Low blood oxygen and a short and steady or rapid growth of hepatocellular carcinoma before the spontaneous remission or regression of hepatocellular carcinoma. It is suggested that the rapid growth of the hepatocellular carcinoma faced with low blood oxygen has possibly resulted in the h...
COVID-19 Post-Vaccinal Lymphadenopathy Mimicking Lymph Node Metastases from Breast Neoplasia
Fabrice FOKOUE, I. Duran DERIJCKERE, Carlos ARTIGAS, Erwin WOFF, Géraldine GEBHART, Denis LARSIMONT and Patrick FLAMEN
Article Type: Case Report | First Published: July 21, 2021
Since the effective start of the large vaccination campaigns against the Coronavirus disease 19 (COVID-19) pandemic, case reports are rising concerning unilateral axillary lymphadenopathies highly uptaking FDG PET/CT scans. These lymphadenopathies can be a source of false positive for FDG PET/CT in a post-vaccination context. We report here the case of a 59-year-old womanfor whom a FDG PET/CT has been performed as part of the initial extension assessment of a recurrence of a left breast, 15 days...
Correlation of PD-L1 Expression with Histological Patterns and Treatment Response in Non-Small Cell Lung Cancer
Boulos Beshai, MD, Shabnam Rehman and Bo Xu, MD
Article Type: Cohort Study | First Published: July 21, 2021
Programmed Death Ligand-1 (PD-L1) inhibitors are currently approved for treatment of advanced stage Non- Small Cell Lung Cancer (NSCLC) patients. We investigated the correlation between PD-L1 expression level in tumor cells by ImmunoHistochemical Method (IHC) to tumor histological growth patterns. Slides or scanned digital images of NSCLC cases tested for PD-L1 between December, 2016 to April, 2018 were blindly re-reviewed to confirm the PD-L1 expression and growth patterns. PD-L1 expression lev...